Table 3– Intra-subject comparison of disease severity during adjacent 3-yr periods of oral contraceptive (OC) use (“exposed” period) and no OC use (“not exposed” period) in females with cystic fibrosis
ParameterFirst 3-yr periodSecond 3-yr period
Exposed periodNot exposed periodp-value#Not exposed periodExposed periodp-value#
Δ FEV1 % pred-0.40 (-22.4–7.55)-2.00 (-16.70–4.85)0.265-1.83 (-15.50–6.60)§-2.35 (-9.30–6.65)§0.426
ΔBMI kg·m−2-0.02 (-0.64–1.64)-0.02 (-1.4–1.54)0.316-0.01 (-1.62–1.30)ƒ-0.27 (-1.87–1.38)ƒ0.618
Total i.v. antibiotics days28 (0–84)+28 (0–168)+0.56742 (0–140)§56 (0–238)§0.725
  • Data are presented as median (range), unless otherwise stated. Females with 3 yrs of OC use (exposed period) followed by 3 yrs of no OC use (not exposed period) or 3 yrs of no OC use (not exposed period) followed by 3 yrs of OC use (exposed period) were included in the analysis. Annual change (Δ) in % predicted forced expiratory volume in 1 s (FEV1 % pred), annual change in body mass index (BMI) and total number of days of intravenous antibiotics were compared for each 3-yr study period. #: p-values indicate comparison between values for age of females; : n=27; +: n=25; §: n=23; ƒ: n=24.